Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shugan Qingre granules (also known as Shu-gan-qing-re formula or SGQR) is a traditional Chinese medicine (TCM) patent formula developed by Beijing Anding Hospital of Capital Medical University for the treatment of generalized anxiety disorder (GAD). Tailored from classic TCM prescriptions such as Xiao-yao powder and Gan-mai-da-zao decoction, the formula is composed of ten herbal ingredients: Radix Paeoniae Alba, Radix Bupleuri, Angelica Sinensis, Radix Curcumae, Poria Cocos, Bulbus Lilii, Cortex Albiziae, Radix Glycyrrhizae, Triticum aestivum L., and Fructus Jujubae. It functions by smoothing liver qi and clearing inner heat, which corresponds to the TCM pattern of fire derived from stagnation of liver-qi. Shugan Qingre granules have been evaluated in clinical trials, including a Phase 4 study comparing its efficacy and safety to buspirone in adults with mild-to-moderate GAD, where it also demonstrated regulatory effects on peripheral blood inflammatory cytokines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shugan Qingre granules.